Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

1
Last update : 29/09/2017
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
American journal of respiratory and critical care medicine 2017 Nov 15;196;1349-1350 2017 Nov 15
Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Lung cancer (Amsterdam, Netherlands) 2017 Jun;108;7-8 2017 Jun

Powered by

  • ^
  • Contact
  • Cookies
  • About